Eduardo Martins
Chief Medical Officer Sagimet Biosciences
Seminars
Thursday 16th April 2026
Managing Gastrointestinal Side Effects of GLP-1 Therapies Through Targeted Receptor Agonism to Improve Patient Tolerability & Increase Treatment Adherence
2:30 pm
- Minimizing common GI side effects, such as nausea and vomiting, through targeted receptor agonism to improve patient tolerability and increase long-term treatment adherence
- Designing therapies to selectively activate GLP-1 receptors in specific tissues to reduce systemic GI effects and provide patients with a better quality of life while on treatment
- Improving patient comfort with fewer gastrointestinal symptoms to ensure greater medication persistence, leading to better and more sustained clinical outcomes
